Replies to post #23393 on Seelos Therapeutics Inc (SEEL)

[value1008]

Thanks for this article, nbm16, which tells me two things: 1) the FDA does perceive there to be a problem with libido in the female population worth treating; 2) APRI's Femprox would most likely be a FAR safer approach (and more effective approach?) to the same problem.